Sentences with phrase «for study patients»

It was not possible for the research team to administer medication or take over clinical responsibility for the study patients.

To determine the length of time it likely took for the study patients» cancers to form, the scientists used multiple statistical models that took into account the patient's age when they were diagnosed and the total number of mutations in each patient's cancer.

Although this human Gut Chip recreated the villus epithelium of normal intestine and enabled new insights into how flow and cyclic peristalsis affects intestinal differentiation and function, it could not be used to study processes that relied on normal intestinal cells from individual donors, which, for example, is crucial for studying patient - specific responses for personalized medicine.

Not exact matches

While the new mid-stage study results from DNDi were impressive (they showed cure rates of 96 % to 97 % even for the sickest patients and those with liver scarring), more late - stage trials will be necessary before the drug is available on a large scale in the developing world.

A new study published in the New England Journal of Medicine finds that Valeant Pharmaceuticals» infamous price hikes for a pair of heart drugs called nitroprusside and isoproterenol — whose prices were increased by 310 % and 720 %, respectively — had significant downstream effects on patient care.

A series of preliminary Mayo Clinic studies conducted in 2010 showed promise for the potential use of a chemical component of green tea (epigallocatechin gallate) in reducing the number of cancer cells in patients with chronic lymphocytic leukemia.

In the asthma study, we found increased odds among asthma patients of asthma hospitalizations, emergency department visits and a medication used for mild asthma attacks with higher unconventional natural gas development activity, compared to those with lower activity.

The study participants were asked to develop strategies for landing the rocket mentally; this, in turn, allowed the patients to strategize ways of blocking out hallucinatory voices inside their heads.

British - based GlaxoSmithKline, for example, conducts more than 100 studies a year in Canada, with the participation of some 10,500 patients in more than 1,000 medical centres.

For example, a small study of 38 patients with Alzheimer's from 2016 looked at the effects of Victoza.

ALKS 3831: Enrollment completed for ENLIGHTEN - 2, a six - month weight study compared to olanzapine in patients with stable schizophrenia.

FITBIT DATA AIDS RESEARCHERS IN UNDERSTANDING SURGERY RECOVERY: Fitbit data can help researchers and doctors predict the risk of 30 - and 60 - day readmission after surgery for cancer patients, according to a study published in the Annals of Behavioral Medicine.

After that, Watson will take assist by providing both physician and patient with a report that includes the most relevant drug trial and academic studies for their specific conditions.

The company points to a simple resource allocation problem that's hindered the most effective patient care: the fact that it is physically impossible for oncologists to keep track of every study, every clinical trial, and every breakthrough in the wildly stratified world of cancer research.

The study offers more validation for the use of remote patient monitoring (RPM) wearables and devices to provide clinicians with fuller, more accurate patient data.

That's because, as a new study notes, meeting patients» basic social needs — including for heating, electricity, food access, and medicines — can actually have a significant effect on basic health indicators like blood pressure and cholesterol levels.

«While we are disappointed CheckMate - 026 did not meet its primary endpoint in this broad patient population, we remain committed to improving patient outcomes through our comprehensive development program, including the ongoing Phase III CheckMate - 227 study exploring the potential of the combination of Opdivo plus [our other cancer immunotherapy] Yervoy for PD - L1 positive patients, and Opdivo plus Yervoy, or Opdivo plus chemotherapy in PD - L1 negative patients,» he added.

Amgen Executive Vice President of Research and Development Sean Harper said the study was designed to explore Kyprolis dosing regimens, noting that the the trial did not meet its goal in improving progression - free survival versus Velcade in patients who had not yet been treated for the disease.

HEART APP IMPROVES JOHNS HOPKINS» PATIENT OUTCOMES: A new cardiology - focused iPhone app is reducing readmission rates for heart attack patients, resulting in massive savings, according to a Johns Hopkins University study.

It may have to do with Addyi's high pricing (on par with Viagra at $ 26 per pill without an assistance program), its daily intake requirement (unlike Viagra, it adds up to $ 780 per month), its potentially deleterious side effects (low blood pressure and fainting), its restrictions on alcohol consumption (abstinence vs. large quantities not recommended for Viagra patients), a 10 % efficacy rate (whereas Viagra works 50 % of the time compared to a placebo, according to a recent study), and its subtle neurotransmitter - targeting mechanism (contrast that to the obvious hydraulics of Viagra).

The study is patient - funded; participants, who range in age from late 30s through 80s, must pay $ 8,000 to take part, and live in or travel to Monterey for treatments and follow - up assessments.

The Food and Drug Administration (FDA) has given Alnylam Pharmaceuticals the green light to relaunch clinical trials of its treatment for the bleeding disorder hemophilia after pausing the studies after a patient death.

Amarin's clinical development program for Vascepa includes a trial known as the REDUCE - IT cardiovascular outcomes study, an 8,175 - patient study commenced in 2011.

For industries like healthcare, Larsen points out that various studies have found that the most «satisfied» patients are also those who spent the most on prescription drugs and were 12 percent more likely to be admitted to hospitals.

In parallel, adjudication will be completed for all MACE which occurred during the study, including adjudication for certain events which, per protocol, can not be finally adjudicated until patients complete their final site visit and results are available from certain non-invasive diagnostic testing conducted during such site visits.

Final patient visits will be followed by completing data entry for the more than 35,000 patient years of study in REDUCE - IT, and typical database quality control measures, known as cleaning.

The National Institutes for Health also brought on six health - care groups in smaller cities to expand the study's reach and ensure a diverse roster of patients.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Dr. Saxon, who spoke with me after her SWSW panel Biometrics and Identity: Beyond Wearable, said that her institution soon will launch a ResearchKit app for an existing study that tracks patients after atrial fibrillation repair surgery.

«Based on the results from these Phase 3 studies, the combination of bictegravir and FTC / TAF could represent an important advance in triple - therapy treatment for a broad range of HIV patients, and we look forward to submitting regulatory applications in the U.S. and EU this year.»

Mosio aims to make mobile technology simple for clients and end users, creating applications that increase patient engagement and improve study adherence requirements through two - way mobile messaging communications, alerts, incentives and surveys.

Join us for key insights from the CoMMpass Study, including results that patients and caregivers may find helpful for treatment decisions.

Interim results showed that a majority of the 22 patients in the two Phase 1/2 studies followed for two years or longer remained free from transfusions.

The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.

Corbus» top - line data from a 22 - patient study of anabasum for the treatment of...

Although the biotech has only conducted preclinical studies so far, there are several potential advantages to nonviral therapies, including being quicker to develop and possibly eliminating the need for a lengthy monitoring period of patients after treatment.

In early September, Alnylam stopped giving doses of its fitusiran drug for a rare bleeding disorder to patients enrolled in clinical studies after the death of a patient.

Patisiran was being evaluated in a late - stage study against a placebo for the treatment of patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy.

For example, Eli Lilly & Co. (NYSE: LLY) has a phase 3 study of solanezumab under way in mild to moderate Alzheimer's disease patients that may slow disease progression by breaking up amyloid plaque buildups thought to be a major cause of the disease.

The last patient enrolled in this study in October 2016, and it sure looks as if investors a bit too eager to call this one a win rather than wait for the final data set.

Chimerix, a biopharmaceutical company that develops antivirals in areas of high unmet medical need, announced in a press release that a Phase 3 study for its SUPPRESS of brincidofovir in patients undergoing...

Cheryl and I were featured on regional and national TV for our contribution to a study about the effects of tango dancing on Parkinson's patients.

In a study, conducted by a faith - based group no less, it was shown that ICU patients who knew they were being prayed for tended to suffer more complications and problems than those who were not or did not know.

The study can only look for an effect from prayers offered as part of the research, they said.They also said they had no explanation for the higher complication rate in patients who knew they were being prayed for, in comparison to patients who only knew it was possible prayers were being said for them.»

«Power of Prayer Flunks Unusual Test — NEW YORK — In the largest study of its kind, researchers found that having people pray for heart bypass surgery patients had no effect on their recovery.

In the Rutgers Study (http://www.templeton.org/pdfs/articles/060331Reuters.pdf), patients who were prayed for did WORSE.

Can you cite studies which show RELIGIOUS counseling has a greater effect, normalizing for the religion of the patient, than non-religious counseling?

«A 1999 follow - up by William S Harris et al. attempted to replicate Byrd's findings under stricter experimental conditions, noting that the original research was not completely blinded and was limited to only «prayer - receptive» individuals (57 of the 450 patients invited to participate in the study refused to give consent «for personal reasons or religious convictions»).

She commends the work, and rightly so, primarily for its «comprehensive critical review of the literature» (there have been about 15 studies of female homosexuals who were not patients) and for its 26 summarized case studies.

If one has never journeyed into the deep — prayed (which includes Scripture / theological study, faith sharing, adoration, spiritual formation / retreats, pilgramages, Mass, reconciliation, fasting, listening for God's voice, and more) on an ongoing fashion or done God's will (been obedient, patient, humble, unconditionally sacrificing, unselfish) to the extent that they understand what it means to be Catholic and God being your number one priority — that His Ways and those of His Church are not the ways of the world (trade vices for virtues) and that we are being called into communion with Him via love for Him and one another in our faith community and broader community — then it is no wonder some are lost or disillusioned.